NEW HAVEN, Conn., Feb. 4, 2019 /PRNewswire/ -- Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a biotechnology company focused on advancing innovative therapies for neurological diseases, today announced that administration of intranasal BHV-3500 in a Phase 1 clinical trial has ...